Caris Life Sciences · 1 day ago
Principal Scientist, Biomarker & Drug Intelligence
Caris Life Sciences is transforming cancer care and changing lives through precision medicine. The Principal Curation Scientist will lead strategic programs to identify high-impact biomarkers and drug candidates, support quality management systems, and engage in cross-functional collaboration to enhance clinical reporting and product strategy.
Artificial Intelligence (AI)BiopharmaBiotechnologyHealth CareLife Science
Responsibilities
Lead strategic programs that continuously scan scientific, clinical-trial, and regulatory pipelines to surface high-impact biomarkers and drug candidates for precision-oncology products and services
Architect and govern enterprise-wide knowledge-management frameworks, setting best-practice standards for cataloging, harmonizing, and integrating multi-omic literature so downstream reporting and analytics remain current
Serve as a scientific spokesperson for designing and delivering high impact presentations and briefings that shape internal product strategy
Support the quality-management system for medical reporting, authoring and approving SOPs, monitoring key quality indicators, and partnering with Regulatory Affairs to ensure compliance
Support the vision and methodology for user-acceptance testing (UAT), by defining test architectures, success criteria, and automation roadmaps that guarantee scalable, fault-tolerant clinical-report updates
Direct cross-functional validation initiatives, unifying data scientists, software engineers, pathologists, and medical directors to stress-test releases and ensure every deliverable meets clinical, operational, and user-experience benchmarks
Champion organizational learning and external engagement, by mentoring scientists across disciplines, spearheading tumor-board and training curricula, and representing the company in consortia, standards bodies, and key scientific forums
Qualification
Required
Ph.D., M.D./Ph.D., or Pharm.D. in a Biological Science related to Cancer Biology or Pharmaceutical Sciences
Minimum of seven years of industry experience in Biopharma, Biotechnology, or a related sector
The position requires the individual to live within the Phoenix, Arizona metropolitan area
Proven experience in curating literature using public databases, tools, and resources
Proficiency with Microsoft Office Suite (Excel, Word, PowerPoint), reference management tools (Endnote), virtual meeting platforms and information mapping/visualization software (e.g., MindManager)
Preferred
More than ten years of experience in the biotechnology and/or pharmaceutical industries is preferred
Strong foundation in Cancer Biology, Molecular and Cellular Biology, Genetics, or a related field relevant to precision medicine in oncology
Familiarity with precision medicine concepts and analytical platforms used to generate proteomic and genomic data for guiding patient therapy
Exceptional communication and presentation skills, with the ability to synthesize complex scientific information into clear, actionable insights for diverse audiences
Demonstrated ability to effectively communicate, coordinate, and build strong relationships across diverse teams and departments to achieve shared goals and alignment throughout projects
Able to analyze complex information, weigh alternatives, and make timely decisions under pressure while considering both short-term impacts and long-term goals
Dedication to achieving high standards of excellence, contributing to the mission of improving patient outcomes in oncology
Experience interpreting clinical data in a clear, accurate, and tailored manner to address the needs of diverse stakeholders including but not limited to healthcare professionals, various cross-functional teams, executive leadership and regulatory bodies
Company
Caris Life Sciences
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
Funding
Current Stage
Public CompanyTotal Funding
$1.86BKey Investors
BraidwellOrbiMedSixth Street
2025-06-18IPO
2025-04-07Private Equity· $168M
2023-01-19Debt Financing· $400M
Recent News
2025-12-22
2025-12-21
2025-12-19
Company data provided by crunchbase